
Pfizer has suffered a blow to its drug development programme with the withdrawal of pulmonary arterial hypertension (PAH) brand Thelin …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

